AMN consolidated revenue increases 32 percent to $887M for full year 2011 AMN Healthcare Providers.
Entering 2012, we are focused on fulfilling our customers’ desire for even more workforce solutions and innovative provider offerings. AMN’s leading position and differentiated value proposition in workforce solutions has place us at the forefront of development and thought leadership inside our sector, stated Susan R. Salka, President and CEO of AMN Healthcare. An indicator of the positive client reaction to our differentiated features was the 20 new MSP contracts won during the year with around $80 million in annualized gross spend under management. We expect these growth developments in MSP and additional workforce solutions to continue. Full Year and 4th Quarter 2011 Results Complete year 2011 consolidated revenue was $887 million, an increase of 32 percent from prior yr.In addition, reductions in brain volume were smaller with fingolimod. Adverse Events Similar proportions of individuals in the three research groups were reported to have adverse events ; the occasions were moderate to moderate in severity in 82 percent of patients getting 0.5 mg of fingolimod, 77 percent of those getting 1.25 mg of fingolimod, and 77 percent of these receiving placebo. Adverse events that led to discontinuation of the analysis medication were more prevalent with fingolimod at a dose of 1 1.25 mg than with fingolimod at a dosage of 0.5 mg or with placebo . Serious adverse occasions were reported for 10.1 percent of patients receiving 0.5 mg of fingolimod, 11.9 percent of those receiving 1.25 mg of fingolimod, and 13.4 percent of these receiving placebo.